Savara Inc. (SVRA)

NASDAQ • Healthcare

$4.22

-$0.32 (-7.0%)

Market open

Last close at October 23, 2026 at 20:00 UTC

Open$4.52

Previous Close$4.22

Day Range$4.13 - $4.58

Avg. Volume (3M)2.7M

Market Cap$867M

52 Week Range

$3.86$7.01

Next EarningsIn 17 daysNov 11, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)

Net Income (TTM)

-$139.3M

EPS (TTM)

-$0.58

ROA (TTM)

-72.5%

Current Ratio

10.13

Dividend Yield

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

-16.7%Q3 2025-$0.14

-7.7%Q4 2025-$0.14

-8.3%Q1 2026-$0.13

-7.1%Q2 2026-$0.15

-13.3%Q3 2026-$0.16

Nov 11

in 17 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Miss -13.3%

Savara’s loss per share trailed consensus in the second fiscal quarter of 2026, based on preliminary results reported August 11, 2026, with EPS of -$0.16 trailing the -$0.14 estimate (difference -$0.02) and down from -$0.14 a year ago. The biotech, which is centered on its molgramostim program for uncommon respiratory conditions, posted GAAP net income of roughly -$40.2 million, a wider loss (net_income YoY -32.3%) versus about -$30.4 million a year earlier, alongside GAAP operating income of around -$41.0 million. Cash burn remained visible, with negative operating cash flow of about -$29.7 million during the quarter, and the company repurchased about $0.0 million of stock. Looking ahead, next-period consensus calls for EPS of -$0.16 on revenue of $500,000.00.

Next report — what to expect

Savara Inc. (SVRA) reports earnings on November 11, 2026. Wall Street’s next-period consensus calls for EPS of -$0.163 on revenue of $500,000.00. In recent history, Savara has beaten EPS in 0 of its 8 most recent quarters, making the upcoming EPS print versus consensus a key focus.

View full earnings history

About Savara Inc.

Savara Inc. is a NASDAQ-listed Biotechnology company focused on medicines for uncommon respiratory conditions. The company centers its work on molgramostim, an inhaled form of granulocyte-macrophage colony-stimulating factor, and it operates as a small-cap developer rather than a commercial diversified drugmaker.

Name

Savara Inc.

CEO

Matthew Pauls

Website

www.savarapharma.com

Industry

Healthcare

Employees

Today's Snapshot

AI-generated

SVRA closed 7% lower at 4.22, in line with a weaker sector.

Trading Volume

Above 10d avg 2.5M

2.6M

vs S&P 500 Today

Strong Underperformance

-6.53%

Updated: October 23, 2026 at 20:10 UTC

Technical Indicators

1 Buy1 Neutral6 Sell

SVRA shows a clear bearish bias as the price sits well below its short, medium and long-term moving averages while volume trends are negative, supporting the strong-sell call. Momentum indicators are weak — MACD and momentum readings are negative and CCI is deeply below zero — even as oscillators suggest short-term oversold conditions. Trend strength is moderate at best, with ADX near the lower end of trend confirmation, while volatility is elevated as ATR is a sizeable percentage of the share price. Technical takeaway: Downside pressure dominates with short-term oversold readings but broad technicals remain strongly negative.

All signals

EMA (5 indicators)$4.61 - $5.32
Sell
RSI (14)31.19
Neutral
Stochastic %K (14, 3, 3)19.37
Buy
MACD Level (12, 26)-0.19
Sell

Peers & Related Assets

TBPHTheravance Biopharma Inc

$17.030.0%

APMDApnimed, Inc.

Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.